Literature DB >> 9847391

Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.

G S Ogg1, X Jin, S Bonhoeffer, P Moss, M A Nowak, S Monard, J P Segal, Y Cao, S L Rowland-Jones, A Hurley, M Markowitz, D D Ho, A J McMichael, D F Nixon.   

Abstract

Little is known of the changes in human immunodeficiency virus type 1 (HIV-1)-specific effector cytotoxic T lymphocytes (CTL) after potent antiretroviral therapy. Using HLA/peptide tetrameric complexes, we show that after starting treatment, there are early rapid fluctuations in the HIV-1-specific CTL response which last 1 to 2 weeks. These fluctuations are followed by an exponential decay (median half-life, 45 days) of HIV-1-specific CTL which continues while viremia remains undetectable. These data have implications for the immunological control of drug-resistant virus.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9847391      PMCID： PMC103892          DOI： 10.1128/JVI.73.1.797-800.1999

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  22 in total

1.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

Review 2.  The CD38 lymphocyte differentiation marker: new insight into its ectoenzymatic activity and its role as a signal transducer.

Authors:  G Shubinsky; M Schlesinger
Journal:  Immunity       Date:  1997-09       Impact factor: 31.745

3.  Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.

Authors:  M A Nowak; S Bonhoeffer; G M Shaw; R M May
Journal:  J Theor Biol       Date:  1997-01-21       Impact factor: 2.691

4.  Identification of multiple HIV-1 cytotoxic T-cell epitopes presented by human leukocyte antigen B35 molecules.

Authors:  H Shiga; T Shioda; H Tomiyama; Y Takamiya; S Oka; S Kimura; Y Yamaguchi; T Gojoubori; H G Rammensee; K Miwa; M Takiguchi
Journal:  AIDS       Date:  1996-09       Impact factor: 4.177

Review 5.  Immunological memory and protective immunity: understanding their relation.

Authors:  R Ahmed; D Gray
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

6.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

7.  Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.

Authors:  Z Liu; W G Cumberland; L E Hultin; H E Prince; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-10-01

8.  CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.

Authors:  A Carr; S Emery; A Kelleher; M Law; D A Cooper
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-12-01

9.  Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1.

Authors:  W B Dyer; G S Ogg; M A Demoitie; X Jin; A F Geczy; S L Rowland-Jones; A J McMichael; D F Nixon; J S Sullivan
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

10.  Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation.

Authors:  P J Goulder; A K Sewell; D G Lalloo; D A Price; J A Whelan; J Evans; G P Taylor; G Luzzi; P Giangrande; R E Phillips; A J McMichael
Journal:  J Exp Med       Date:  1997-04-21       Impact factor: 14.307
View more
  128 in total

1.  Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression.

Authors:  G S Ogg; S Kostense; M R Klein; S Jurriaans; D Hamann; A J McMichael; F Miedema
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  The challenge of immune control of immunodeficiency virus.

Authors:  D Richman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Authors:  M Dalod; M Dupuis; J C Deschemin; C Goujard; C Deveau; L Meyer; N Ngo; C Rouzioux; J G Guillet; J F Delfraissy; M Sinet; A Venet
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 4.  Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy.

Authors:  G R Kaufmann; J Zaunders; D A Cooper
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

5.  MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy.

Authors:  J N Blankson; R F Siliciano
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

6.  HIV therapy: managing resistance.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

7.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

8.  Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection.

Authors:  Marcus Altfeld; Jan van Lunzen; Nicole Frahm; Xu G Yu; Claus Schneider; Robert L Eldridge; Margaret E Feeney; Dirk Meyer-Olson; Hans-Juergen Stellbrink; Bruce D Walker
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

Review 9.  Immunological effects of interleukin-2 therapy in human immunodeficiency virus-positive subjects.

Authors:  P De Paoli
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

10.  Immune Reconstitution Strategies in HIV.

Authors:  Matthew R. Leibowitz; Ronald T. Mitsuyasu
Journal:  Curr Infect Dis Rep       Date:  2001-06       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.